Early intensive therapy with autotransplantation for high-risk XXXX .

@entity1 @entity137 @entity5 @entity786 @entity2541 @entity2033 @entity2879 @entity1398 @entity5501 @entity401 @entity978
The purpose of this trial was to evaluate the efficacy and the tolerance of high-dose therapy with autologous stem cell transplantation as part of front-line therapy in @entity978 for @entity1 with both adverse prognostic factors: high @entity5 burden at presentation and slow response to initial chemotherapy. In a prospective one-center study, 20 consecutive @entity1 with slow response ( @entity5 reduction < 75%) (16 pts) or refractory (4 pts) to 3-4 courses of conventional @entity2033 chemotherapy received high-dose therapy followed with autologous bone marrow (14 pts) or peripheral blood stem cell (6 pts) transplantation. They were 13 males, 7 females, median age 26 years (8-45). At the time of initial diagnosis, all but one of the @entity1 had B symptoms, all had high-risk @entity2033 defined as Ann Arbor stage IV (7 pts) or large mediastinal involvement (LMI = @entity5 /thorax > 0.45 at T5-T6) (6 pts) or both stage IV+LMI (7 pts). Median time between diagnosis and autotransplantation was 5 months. Intensive therapy consisted of either @entity2541 ( @entity786 1.5 g/m2 x 4, BCNU 300 mg/m2, @entity2879 200 mg/m2 x 3) (12 pts) or @entity786 120 mg/kg + 12 Gy total body irradiation for 8 @entity1 with diffuse bone or lung involvement. For pts treated with CBV, 40 Gy involved field radio-therapy was performed after hematological recovery. Median duration of @entity1398 was 16 days (9-21). Neither @entity5501 , nor @entity401 nor @entity137 death were observed. Seventeen pts are alive with no progression of the disease (16/16 in partial response after initial chemotherapy, 1/4 with refractory disease).(ABSTRACT TRUNCATED AT 250 WORDS)
